New drug aims to wake up the immune system to fight advanced cancers

NCT ID NCT06923761

Recruiting now Disease control Sponsor: Grey Wolf Therapeutics Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new oral drug called GRWD5769, which is designed to help the body's immune system recognize and attack cancer cells. It will be given alone and in combination with an existing immunotherapy drug (cemiplimab/Libtayo®) to adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the treatment can shrink tumors or slow their growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alfred Health
RECRUITING

Melbourne, Australia
Austin Health
RECRUITING

Heidelberg, Australia
Blacktown Hospital
RECRUITING

Blacktown, Australia
Cancer Care Wollongong
RECRUITING

Wollongong, Australia
Centre Eugène Marquis
RECRUITING

Rennes, France
Centre Léon Bérard
RECRUITING

Lyon, France
Christie NHS Foundation Trust
RECRUITING

Manchester, United Kingdom
Clatterbridge Cancer Centre
RECRUITING

Liverpool, United Kingdom
Clinica Universitaria de Navarra Madrid
RECRUITING

Madrid, Spain
Clinica Universitaria de Navarra Pamplona
RECRUITING

Pamplona, Spain
GenesisCare Research
WITHDRAWN

Adelaide, Australia
Hammersmith Hospitals NHS Trust
RECRUITING

London, United Kingdom
Hospital Universitario Vall d'Hebrón (VHIO)
RECRUITING

Barcelona, Spain
Hospital Universitario Virgen de la Victoria
RECRUITING

Málaga, Spain
ICANS - Institut de Cancérologie Strasbourg
RECRUITING

Strasbourg, France
INCLIVA-Hospital Clínico Universitario de Valencia
RECRUITING

Valencia, Spain
IUCT Oncopole - Institut Claudius Regaud
RECRUITING

Toulouse, France
Institut Gustave Roussy
RECRUITING

Villejuif, France
Institut Paoli-Calmettes
RECRUITING

Marseille, France
Institut de Cancérologie de l'Ouest (ICO)
RECRUITING

Saint-Herblain, France
Kinghorn Cancer Centre (KCC)
RECRUITING

Darlinghurst, Australia
Mater Research
RECRUITING

South Brisbane, Australia
Newcastle Upon Tyne Hospital
RECRUITING

Newcastle, United Kingdom
Royal Free Hospital
RECRUITING

London, United Kingdom
START Barcelona - Hospital HM Nou Delfos
RECRUITING

Barcelona, Spain
START Madrid - Centro Integral Oncológico Clara Campal (HM CIOCC)
RECRUITING

Madrid, Spain
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
RECRUITING

Madrid, Spain
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITING

Bedford Park, Australia
Western General Hospital
RECRUITING

Edinburgh, United Kingdom

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID MALIGNANCY